EGFR and non-small cell lung carcinoma: Many clinical trials have demonstrated the superiority of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) over chemotherapy in the treatment of patients with advanced NSCLC harboring EGFR mutations (Maemondo et al., 2010; Mitsudomi et al., 2010; Rosell et al., 2012; Yang et al., 2013; Wu et al., 2014).